null Larry Lands, MD, PhD
Cystic fibrosis (CF) • asthma • immune modulation • physical activity • translational research
My research focuses on children with lung diseases, such as asthma and cystic fibrosis, who have excessive inflammation in their lungs. This often limits their ability to be physically active. I study how to calm down lung inflammation, boost immune defences, and improve physical performance. In our laboratory we are attempting to increase natural immunity to respiratory viral infections, to prevent people with chronic lung disease from becoming sicker when they catch a cold. The immune-boosting abilities of vitamin D are also being examined, as are the immune- and performance-enhancing properties of our novel whey protein supplement. And to help patients benefit from an active lifestyle, we are studying a new motivational program to encourage physical activity in patients with cystic fibrosis.
Dauletbaev N, Cammisano M, Herscovitch K, Lands LC. Targeted stimulation of antiviral interferon-beta in airway epithelial cells and macrophages with minimal concomitant inflammation. J Immunol 195(6):2829-41, 2015.
Dauletbaev N, Herscovitch K, Das M, Bernier J, Matouk E, Bérubé J, Rousseau S, Lands LC. Down-regulation of IL-8 in macrophages by vitamin D is individualized, requires high doses, and involves mechanisms beyond up-regulation of DUSP1. Br J Pharmacology 195(6):2829-41, 2015.
Hebestreit H, Arets HG, Aurora P, Boas S, Cerny F, Hulzebos EH, Karila C, Lands LC, Lowman JD, Swisher A, Urquhart DS; European Cystic Fibrosis Society Exercise Working Group. Statement on exercise testing in cystic fibrosis. Respiration 90(4):332-51, 2015.
Mak, DYF, Sykes J, Stephenson AL, Lands LC. The benefits of newborn screening for cystic fibrosis: The Canadian Experience. J CF 2016 May;15(3):302-8.
Middleton PG, Mall MA, Dřevínek P, Lands LC, McKone EF, Polineni D, Ramsey BW, Taylor-Cousar JL, Tullis E, Vermeulen F, Marigowda G, McKee CM, Moskowitz SM, Nair N, Savage J, Simard C, Tian S, Waltz D, Xuan F, Rowe SM, Jain R; VX17-445-102 Study Group. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. N Engl J Med. 2019 Nov 7;381(19):1809-1819.